pemetrexed,carboplatin,paclitaxel,vinorelbine,nivolumab,cisplatin,docetaxel,gemcitabine,ipilimumab,pembrolizumab
merck,bms
[]
 i'm dubious adjuvant adds much if cancer was resistant to 1st 4 cycles, but if 75% of pts have residual viable dzs &amp; high risk of relapse, you're choosing between risk of over-treatment vs. under-treatment. you discuss w/pt, but suspect most favor erring on over-treatment.
Med Onc,@CityofHope; VP Netwk Strategy AccessHope, Founder,@CancerGRACE; Web Ed,@JAMAOnc; Author/Ed, @UptoDate

Telemed/digital med fan. 
Disclosures @ website